美的集團(000333.SZ):向1897名激勵對象授予8226萬份股票期權
格隆匯6月6日丨美的集團(000333.SZ)公佈,根據美的集團2020年年度股東大會授權,公司於2021年6月4日召開第三屆董事會第三十四次會議,審議通過了《關於調整公司第八期股票期權激勵計劃行權價格、激勵對象名單及授予數量的議案》,根據2020年度利潤分配的實施安排,第八期股票期權激勵計劃的行權價格由82.98元/股調整為81.41元/股。同時因激勵對象離職原因對第八期股權激勵計劃激勵對象及授予數量進行相應調整。經調整,第八期股權激勵計劃的激勵對象由1901名變更為1897名,股票期權總量由8248萬份調整為8226萬份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.